Scientific Studies

Flu-X has undergone numerous scientific studies and animal and human patient clinical trials, based on strict and rigorous pharmaceutical and WHO protocols, which demonstrate and confirm that Flu-X kills both Influenza A & B viruses upon contact, thus preventing contraction of the flu* and, further, prevents the replication of both Influenza A & B viruses, thereby preventing and reducing the severity of flu and colds and accelerating recovery*. A summary of some of these studies and clinical trials is presented below:

• A 153 patient placebo-controlled clinical trial of patients with Viral Respiratory Tract Infection demonstrated an 82.9% three day recovery rate in the Flu-X group compared to 19.6% in the placebo (untreated) control group (see chart below).
   

Administration Group	Total Patients	Row #1 - No. of Administration days Row #2 - No. of cases recovered Row #3 - Recovery rate
		Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Viral Respiratory Tract Infection	82	31	30	7	6	3	3	2
		37.8%	36.6%	8.5%	7.3%	3.8%	3.6%	2.4%
Non-Administration (Placebo) Group	Total Patients	No. of recovery cases, recovery rate
		Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Viral Respiratory Tract Infection	71	0	5	9	31	20	3	3
		0%	7%	12.6%	43.7%	28.1%	4.4%	4.2%

 

     Notes:

1. Viral Respiratory Tract Infection includes the common cold and anginosis, etc.
2. Clinical trial patients were aged 6 to 72, with 79 males and 75 females.

• A clinical trial of 1,000 volunteer adults and children, of both sexes, with confirmed flu symptoms and infection, that were treated with Flu-X, demonstrated an 87.8% three-day recovery rate from their flu symptoms and infection.
• Comparative in-vivo studies on sixty Influenza-induced mice confirm Flu-X’s superiority to Interferon (a leading anti-viral pharmaceutical) against the Influenza virus, offering a protection rate of 55%, compared to only 40% for Interferon, and 10% for the non-treated, control group.
• In-vivo, viral inactivation studies conducted at the China Centres for Disease Control (CDC) on 11 day old chick embryos injected with the Influenza A and B viruses demonstrated inactivated virus indicies (EID₅₀/0.2 ml Flu-X) of greater than 10^6.75. The effective inactivation concentrations of Flu-X were EC₅₀=37.1 mg/ml and EC₉₀=77.7 mg/ml.
• In-vivo bacteriological screening of Flu-X against the three bacterial strains known to commonly infect the human respiratory tract - H.influenza, Aureus staphylococcus and A-hemolytic streptococcus - note: H.influenza is the main cause of epidemic meningitis - confirmed the Flu-X compound (at 45% concentration) inhibited these bacterial strains in comparison to both positive (Penicillin) and negative (NaCl) control groups.

Product Safety

The result of almost three years of extensive clinical research & development, Flu-X is a highly effective, natural, herbal, over-the-counter (OTC), oral anti-flu spray and is a patented scientific formulation of five standardized Chinese herb extracts. Developed by Professor D. S. Liu, Ph.D, one of China's most eminent and respectable virologists and medical doctors, Flu-X began originally as an anti-SARS virus drug during China's SARS epidemic in 2003. Due to its strong ant-viral properties the product was successfully used to treat SARS infected patients and prevent SARS infection at several hospitals in China.

Long and short term clinical toxicology studies conducted on the product confirm Flu-X to be safe even at 400 times the recommended human dosage. Additionally, the product has been used by over 1,000 volunteers and has been shown to be safe and highly effective in the prevention and treatment of influenza, by killing and preventing the replication of the Influenza A & B viruses*.

Click here for Toxicological Studies.